Cardiac manifestations in antiphospholipid syndrome

P. Soltész, Z. Szekanecz, E. Kiss, Yehuda Shoenfeld

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Antiphospholipid syndrome (APS) is a systemic autoimmune disease associated with arterial and venous thrombotic events and recurrent fetal loss. Cardiac manifestations in APS primarily include accelerated atherosclerosis leading to cardiovascular disease. There is increased cardiovascular mortality in APS. Cardiovascular risk is even higher in secondary APS in lupus patients. Several traditional and disease-related, autoimmune-inflammatory risk factors are involved in APS-associated atherosclerosis and its clinical manifestations. Antiphospholipid antibodies (APA), lupus anticoagulant, anti-oxLDL and other antibodies have been implicated in vascular events underlying APS. The primary and secondary prevention of atherosclerosis and CAD in these diseases includes drug treatment, such as the use of statins and aspirin, as well as lifestyle modifications. Apart from atherosclerosis and CVD, other cardiac manifestations may also be present in these patients. Among these conditions, valvular disease including thickening and vegetations is the most common. APA are involved in the pathogenesis of Libman-Sacks endocarditis usually associated with SLE. In addition, ventricular dysfunction, intracardiac thrombi and myxomas, pulmonary hypertension may also exist in APS patients. Early diagnosis of APS, thorough examination of the heart, control of traditional risk factors by lifestyle modifications and pharmacotherapy, probably anti-inflammatory treatment, and close follow-up of APS patients may help to minimize cardiovascular risk in these individuals.

Original languageEnglish
Pages (from-to)379-386
Number of pages8
JournalAutoimmunity Reviews
Volume6
Issue number6
DOIs
Publication statusPublished - Jun 2007

Fingerprint

Antiphospholipid Syndrome
Atherosclerosis
Antiphospholipid Antibodies
Autoimmune Diseases
Life Style
Ventricular Dysfunction
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lupus Coagulation Inhibitor
Primary Prevention
Secondary Prevention
Endocarditis
Pulmonary Hypertension
Aspirin
Blood Vessels
Early Diagnosis
Thrombosis
Anti-Inflammatory Agents
Cardiovascular Diseases
Drug Therapy
Mortality

Keywords

  • Antiphospholipid syndrome
  • Atherosclerosis
  • Cardiac manifestations
  • Cardiovascular disease

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Cardiac manifestations in antiphospholipid syndrome. / Soltész, P.; Szekanecz, Z.; Kiss, E.; Shoenfeld, Yehuda.

In: Autoimmunity Reviews, Vol. 6, No. 6, 06.2007, p. 379-386.

Research output: Contribution to journalArticle

@article{db77c174b89a48789a8259b276e48c40,
title = "Cardiac manifestations in antiphospholipid syndrome",
abstract = "Antiphospholipid syndrome (APS) is a systemic autoimmune disease associated with arterial and venous thrombotic events and recurrent fetal loss. Cardiac manifestations in APS primarily include accelerated atherosclerosis leading to cardiovascular disease. There is increased cardiovascular mortality in APS. Cardiovascular risk is even higher in secondary APS in lupus patients. Several traditional and disease-related, autoimmune-inflammatory risk factors are involved in APS-associated atherosclerosis and its clinical manifestations. Antiphospholipid antibodies (APA), lupus anticoagulant, anti-oxLDL and other antibodies have been implicated in vascular events underlying APS. The primary and secondary prevention of atherosclerosis and CAD in these diseases includes drug treatment, such as the use of statins and aspirin, as well as lifestyle modifications. Apart from atherosclerosis and CVD, other cardiac manifestations may also be present in these patients. Among these conditions, valvular disease including thickening and vegetations is the most common. APA are involved in the pathogenesis of Libman-Sacks endocarditis usually associated with SLE. In addition, ventricular dysfunction, intracardiac thrombi and myxomas, pulmonary hypertension may also exist in APS patients. Early diagnosis of APS, thorough examination of the heart, control of traditional risk factors by lifestyle modifications and pharmacotherapy, probably anti-inflammatory treatment, and close follow-up of APS patients may help to minimize cardiovascular risk in these individuals.",
keywords = "Antiphospholipid syndrome, Atherosclerosis, Cardiac manifestations, Cardiovascular disease",
author = "P. Solt{\'e}sz and Z. Szekanecz and E. Kiss and Yehuda Shoenfeld",
year = "2007",
month = "6",
doi = "10.1016/j.autrev.2007.01.003",
language = "English",
volume = "6",
pages = "379--386",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Cardiac manifestations in antiphospholipid syndrome

AU - Soltész, P.

AU - Szekanecz, Z.

AU - Kiss, E.

AU - Shoenfeld, Yehuda

PY - 2007/6

Y1 - 2007/6

N2 - Antiphospholipid syndrome (APS) is a systemic autoimmune disease associated with arterial and venous thrombotic events and recurrent fetal loss. Cardiac manifestations in APS primarily include accelerated atherosclerosis leading to cardiovascular disease. There is increased cardiovascular mortality in APS. Cardiovascular risk is even higher in secondary APS in lupus patients. Several traditional and disease-related, autoimmune-inflammatory risk factors are involved in APS-associated atherosclerosis and its clinical manifestations. Antiphospholipid antibodies (APA), lupus anticoagulant, anti-oxLDL and other antibodies have been implicated in vascular events underlying APS. The primary and secondary prevention of atherosclerosis and CAD in these diseases includes drug treatment, such as the use of statins and aspirin, as well as lifestyle modifications. Apart from atherosclerosis and CVD, other cardiac manifestations may also be present in these patients. Among these conditions, valvular disease including thickening and vegetations is the most common. APA are involved in the pathogenesis of Libman-Sacks endocarditis usually associated with SLE. In addition, ventricular dysfunction, intracardiac thrombi and myxomas, pulmonary hypertension may also exist in APS patients. Early diagnosis of APS, thorough examination of the heart, control of traditional risk factors by lifestyle modifications and pharmacotherapy, probably anti-inflammatory treatment, and close follow-up of APS patients may help to minimize cardiovascular risk in these individuals.

AB - Antiphospholipid syndrome (APS) is a systemic autoimmune disease associated with arterial and venous thrombotic events and recurrent fetal loss. Cardiac manifestations in APS primarily include accelerated atherosclerosis leading to cardiovascular disease. There is increased cardiovascular mortality in APS. Cardiovascular risk is even higher in secondary APS in lupus patients. Several traditional and disease-related, autoimmune-inflammatory risk factors are involved in APS-associated atherosclerosis and its clinical manifestations. Antiphospholipid antibodies (APA), lupus anticoagulant, anti-oxLDL and other antibodies have been implicated in vascular events underlying APS. The primary and secondary prevention of atherosclerosis and CAD in these diseases includes drug treatment, such as the use of statins and aspirin, as well as lifestyle modifications. Apart from atherosclerosis and CVD, other cardiac manifestations may also be present in these patients. Among these conditions, valvular disease including thickening and vegetations is the most common. APA are involved in the pathogenesis of Libman-Sacks endocarditis usually associated with SLE. In addition, ventricular dysfunction, intracardiac thrombi and myxomas, pulmonary hypertension may also exist in APS patients. Early diagnosis of APS, thorough examination of the heart, control of traditional risk factors by lifestyle modifications and pharmacotherapy, probably anti-inflammatory treatment, and close follow-up of APS patients may help to minimize cardiovascular risk in these individuals.

KW - Antiphospholipid syndrome

KW - Atherosclerosis

KW - Cardiac manifestations

KW - Cardiovascular disease

UR - http://www.scopus.com/inward/record.url?scp=34249326608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249326608&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2007.01.003

DO - 10.1016/j.autrev.2007.01.003

M3 - Article

VL - 6

SP - 379

EP - 386

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 6

ER -